Hsp90: Still a viable target in prostate cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 2, 2013, Pages 211-218

  Centenera, Margaret M ^a   Fitzpatrick, Alyssa K ^a   Tilley, Wayne D ^a   Butler, Lisa M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Clinical trials; Hsp90; Inhibitors; Prostate cancer

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ALVESPIMYCIN; ANDROGEN RECEPTOR; AT 13387; AT 133887; BICALUTAMIDE; CISPLATIN; CYTOCHROME P450 3A5; DOCETAXEL; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMITRINIB; GANETESPIB; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; KU 174; MULTIDRUG RESISTANCE PROTEIN; NOVOBIOCIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; RADICICOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RETASPIMYCIN; SNX 2112; TANESPIMYCIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG METABOLISM; DRUG RESEARCH; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERABILITY; EYE TOXICITY; HUMAN; KETOACIDOSIS; LIVER TOXICITY; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN STRUCTURE; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

DRUG DISCOVERY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84873113240     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.12.005     Document Type: Review

References (100)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351:1502-1512.
3. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W., Schellhammer P.F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363:411-422.
4. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., Gravis G., Bodrogi I., Mackenzie M.J., Shen L., Roessner M., Gupta S., Sartor A.O. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
5. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones R.J., Goodman O.B., Saad F., Staffurth J.N., Mainwaring P., Harland S., Flaig T.W., Hutson T.E., Cheng T., Patterson H., Hainsworth J.D., Ryan C.J., Sternberg C.N., Ellard S.L., Flechon A., Saleh M., Scholz M., Efstathiou E., Zivi A., Bianchini D., Loriot Y., Chieffo N., Kheoh T., Haqq C.M., Scher H.I. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011, 364:1995-2005.
6. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller M.D., de Wit R., Mulders P., Chi K.N., Shore N.D., Armstrong A.J., Flaig T.W., Flechon A., Mainwaring P., Fleming M., Hainsworth J.D., Hirmand M., Selby B., Seely L., de Bono J.S. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 2012, 367:1187-1197.
7. Scher H.I., Fizazi K., Saad F., Taplin M.-E., Sternberg C.N., Miller K., De Wit R., Mulders P., Hirmand M., Selby B., De Bono J.S. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J. Clin. Oncol. 2012, 30:LBA1. for the AFFIRM Investigators.
8. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10:537-549.
9. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
10. Calderwood S.K., Khaleque M.A., Sawyer D.B., Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci. 2006, 31:164-172.
11. Dai C., Whitesell L., Rogers A.B., Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130:1005-1018.
12. Min J.N., Huang L., Zimonjic D.B., Moskophidis D., Mivechi N.F. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 2007, 26:5086-5097.
13. Sreedhar A.S., Kalmar E., Csermely P., Shen Y.F. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004, 562:11-15.
14. Voss A.K., Thomas T., Gruss P. Mice lacking HSP90beta fail to develop a placental labyrinth. Development 2000, 127:1-11.
15. Pearl L.H., Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75:271-294.
16. Wandinger S.K., Richter K., Buchner J. The Hsp90 chaperone machinery. J. Biol. Chem. 2008, 283:18473-18477.
17. Scaltriti M., Dawood S., Cortes J. Molecular pathways: targeting hsp90-who benefits and who does not. Clin. Cancer Res. 2012, 18:4508-4513.
18. Haupt A., Joberty G., Bantscheff M., Frohlich H., Stehr H., Schweiger M.R., Fischer A., Kerick M., Boerno S.T., Dahl A., Lappe M., Lehrach H., Gonzalez C., Drewes G., Lange B.M. Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics. BMC Cancer 2012, 12:38.
19. Cardillo M.R., Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res. 2006, 26:3409-3416.
20. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
21. Waltering K.K., Urbanucci A., Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol. Cell. Endocrinol. 2012, 360:38-43.
22. He S., Zhang C., Shafi A.A., Sequeira M., Acquaviva J., Friedland J.C., Sang J., Smith D.L., Weigel N.L., Wada Y., Proia D.A. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int. J. Oncol. 2013, 42:35-43.
23. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. Inhibition of heat shock protein HSP90-pp 60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8324-8328.
24. Sharma S.V., Agatsuma T., Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998, 16:2639-2645.
25. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42:260-266.
26. Esser C., Alberti S., Hohfeld J. Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim. Biophys. Acta 2004, 1695:171-188.
27. McClellan A.J., Tam S., Kaganovich D., Frydman J. Protein quality control: chaperones culling corrupt conformations. Nat. Cell Biol. 2005, 7:736-741.
28. Connell P., Ballinger C.A., Jiang J., Wu Y., Thompson L.J., Hohfeld J., Patterson C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 2001, 3:93-96.
29. Ballinger C.A., Connell P., Wu Y., Hu Z., Thompson L.J., Yin L.Y., Patterson C. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 1999, 19:4535-4545.
30. Supko J.G., Hickman R.L., Grever M.R., Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 1995, 36:305-315.
31. Soga S., Shiotsu Y., Akinaga S., Sharma S.V. Development of radicicol analogues. Curr. Cancer Drug Targets 2003, 3:359-369.
32. Solit D.B., Zheng F.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., Heller G., Tong W., Cordon-Cardo C., Agus D.B., Scher H.I., Rosen N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 2002, 8:986-993.
33. Williams C.R., Tabios R., Linehan W.M., Neckers L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J. Urol. 2007, 178:1528-1532.
34. Ramanathan R.K., Trump D.L., Eiseman J.L., Belani C.P., Agarwala S.S., Zuhowski E.G., Lan J., Potter D.M., Ivy S.P., Ramalingam S., Brufsky A.M., Wong M.K., Tutchko S., Egorin M.J. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res. 2005, 11:3385-3391.
35. Goetz M.P., Toft D., Reid J., Ames M., Stensgard B., Safgren S., Adjei A.A., Sloan J., Atherton P., Vasile V., Salazaar S., Adjei A., Croghan G., Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol. 2005, 23:1078-1087.
36. Banerji U., O'Donnell A., Scurr M., Pacey S., Stapleton S., Asad Y., Simmons L., Maloney A., Raynaud F., Campbell M., Walton M., Lakhani S., Kaye S., Workman P., Judson I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 2005, 23:4152-4161.
37. Grem J.L., Morrison G., Guo X.D., Agnew E., Takimoto C.H., Thomas R., Szabo E., Grochow L., Grollman F., Hamilton J.M., Neckers L., Wilson R.H. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol. 2005, 23:1885-1893.
38. Heath E.I., Hillman D.W., Vaishampayan U., Sheng S., Sarkar F., Harper F., Gaskins M., Pitot H.C., Tan W., Ivy S.P., Pili R., Carducci M.A., Erlichman C., Liu G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 2008, 14:7940-7946.
39. Chiosis G., Caldas Lopes E., Solit D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr. Opin. Investig. Drugs 2006, 7:534-541.
40. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 1999, 91:1940-1949.
41. Egorin M.J., Rosen D.M., Wolff J.H., Callery P.S., Musser S.M., Eiseman J.L. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res. 1998, 58:2385-2396.
42. Sausville E.A., Tomaszewski J.E., Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets 2003, 3:377-383.
43. Hollingshead M., Alley M., Burger A.M., Borgel S., Pacula-Cox C., Fiebig H.H., Sausville E.A. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother. Pharmacol. 2005, 56:115-125.
44. Sharp S.Y., Kelland L.R., Valenti M.R., Brunton L.A., Hobbs S., Workman P. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol. Pharmacol. 2000, 58:1146-1155.
45. Pacey S., Wilson R.H., Walton M.I., Eatock M., Hardcastle A., Zetterlund A., Arkenau H.T., Moreno-Farre J., Banerji U., Roels B., Peachey H., Aherne W., de Bono J.S., Raynaud F.I., Workman P., Judson I.R. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced, solid tumors. Clin. Cancer Res. 2011, 17:1561-1570.
46. Sydor J.R., Normant E., Pien C.S., Porter J.R., Ge J., Grenier L., Pak R.H., Ali J.A., Dembski M.S., Hudak J., Patterson J., Penders C., Pink M., Read M.A., Sang J., Woodward C., Zhang Y., Grayzel D.S., Wright J., Barrett J.A., Palombella V.J., Adams J., Tong J.K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17408-17413.
47. Oh W.K., Galsky M.D., Stadler W.M., Srinivas S., Chu F., Bubley G., Goddard J., Dunbar J., Ross R.W. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 2011, 78:626-630.
48. Taldone T., Sun W., Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg. Med. Chem. 2009, 17:2225-2235.
49. Jhaveri K., Taldone T., Modi S., Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim. Biophys. Acta 2011, 1823:742-755.
50. Chan C.T., Reeves R.E., Geller R., Yaghoubi S.S., Hoehne A., Solow-Cordero D.E., Chiosis G., Massoud T.F., Paulmurugan R., Gambhir S.S. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2476-2485.
51. Lamoureux F., Thomas C., Yin M.J., Kuruma H., Fazli L., Gleave M.E., Zoubeidi A. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin. Cancer Res. 2011, 17:2301-2313.
52. Yano A., Tsutsumi S., Soga S., Lee M.J., Trepel J., Osada H., Neckers L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15541-15546.
53. Rajan A., Kelly R.J., Trepel J.B., Kim Y.S., Alarcon S.V., Kummar S., Gutierrez M., Crandon S., Zein W.M., Jain L., Mannargudi B., Figg W.D., Houk B.E., Shnaidman M., Brega N., Giaccone G. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin. Cancer Res. 2011, 17:6831-6839.
54. Eccles S.A., Massey A., Raynaud F.I., Sharp S.Y., Box G., Valenti M., Patterson L., de Haven Brandon A., Gowan S., Boxall F., Aherne W., Rowlands M., Hayes A., Martins V., Urban F., Boxall K., Prodromou C., Pearl L., James K., Matthews T.P., Cheung K.M., Kalusa A., Jones K., McDonald E., Barril X., Brough P.A., Cansfield J.E., Dymock B., Drysdale M.J., Finch H., Howes R., Hubbard R.E., Surgenor A., Webb P., Wood M., Wright L., Workman P. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68:2850-2860.
55. Centenera M.M., Gillis J.L., Hanson A., Jindal S., Taylor R.A., Risbridger G., Sutherland P.D., Scher H.I., Raj G.V., Knudsen K.E., Yeadon T., Tilley W.D., Butler L.M. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin. Cancer Res. 2012, 18:1-9.
56. Gaspar N., Sharp S.Y., Eccles S.A., Gowan S., Popov S., Jones C., Pearson A., Vassal G., Workman P. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol. Cancer Ther. 2010, 9:1219-1233.
57. Jensen M.R., Schoepfer J., Radimerski T., Massey A., Guy C.T., Brueggen J., Quadt C., Buckler A., Cozens R., Drysdale M.J., Garcia-Echeverria C., Chene P. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 2008, 10:R33.
58. Monazzam A., Razifar P., Ide S., Rugaard Jensen M., Josephsson R., Blomqvist C., Langstrom B., Bergstrom M. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. Nucl. Med. Biol. 2009, 36:335-342.
59. Samuel T.A., Sessa C., Britten C., Milligan K.S., Mita M.M., Banerji U., Pluard T.J., Stiegler P., Quadt C., Shapiro G. AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. ASCO Meet. Abstr. 2010, 28:2528.
60. Onozawa Y., Doi T., Yamazaki K., Watanabe J., Fuse N., Yoshino T., Akimov M., Robson M., Boku N., Ohtsu A. Abstract B98: AUY922, a novel HSP90 inhibitor: final results of a phase I dose escalation study in Japanese patients with advanced solid malignancies. Mol. Cancer Ther. 2011, 10:B98.
61. McCleese J.K., Bear M.D., Fossey S.L., Mihalek R.M., Foley K.P., Ying W., Barsoum J., London C.A. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int. J. Cancer 2009, 125:2792-2801.
62. Ying W., Du Z., Sun L., Foley K.P., Proia D.A., Blackman R.K., Zhou D., Inoue T., Tatsuta N., Sang J., Ye S., Acquaviva J., Ogawa L.S., Wada Y., Barsoum J., Koya K. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol. Cancer Ther. 2012, 11:475-484.
63. Proia D.A., Foley K.P., Korbut T., Sang J., Smith D., Bates R.C., Liu Y., Rosenberg A.F., Zhou D., Koya K., Barsoum J., Blackman R.K. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 2011, 6:e18552.
64. Woodhead A.J., Angove H., Carr M.G., Chessari G., Congreve M., Coyle J.E., Cosme J., Graham B., Day P.J., Downham R., Fazal L., Feltell R., Figueroa E., Frederickson M., Lewis J., McMenamin R., Murray C.W., O'Brien M.A., Parra L., Patel S., Phillips T., Rees D.C., Rich S., Smith D.M., Trewartha G., Vinkovic M., Williams B., Woolford A.J. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem. 2010, 53:5956-5969.
65. Graham B., Curry J., Smyth T., Fazal L., Feltell R., Harada I., Coyle J., Williams B., Reule M., Angove H., Cross D.M., Lyons J., Wallis N.G., Thompson N.T. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci. 2012, 103:522-527.
66. Mahadevan D., Rensvold D.M., Kurtin S.E., Cleary J.M., Gandhi L., Lyons J.F., Lock V., Lewis S., Shapiro G. First-in-human phase I study: results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors. ASCO Meet. Abstr. 2012, 30:3028.
67. Marcu M.G., Chadli A., Bouhouche I., Catelli M., Neckers L.M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275:37181-37186.
68. Matthews S.B., Vielhauer G.A., Manthe C.A., Chaguturu V.K., Szabla K., Matts R.L., Donnelly A.C., Blagg B.S., Holzbeierlein J.M. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate 2010, 70:27-36.
69. Eskew J.D., Sadikot T., Morales P., Duren A., Dunwiddie I., Swink M., Zhang X., Hembruff S., Donnelly A., Rajewski R.A., Blagg B.S., Manjarrez J.R., Matts R.L., Holzbeierlein J.M., Vielhauer G.A. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 2011, 11:468.
70. Kang B.H., Plescia J., Dohi T., Rosa J., Doxsey S.J., Altieri D.C. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007, 131:257-270.
71. Kang B.H., Plescia J., Song H.Y., Meli M., Colombo G., Beebe K., Scroggins B., Neckers L., Altieri D.C. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 2009, 119:454-464.
72. Kang B.H., Siegelin M.D., Plescia J., Raskett C.M., Garlick D.S., Dohi T., Lian J.B., Stein G.S., Languino L.R., Altieri D.C. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin. Cancer Res. 2010, 16:4779-4788.
73. Kang B.H., Tavecchio M., Goel H.L., Hsieh C.C., Garlick D.S., Raskett C.M., Lian J.B., Stein G.S., Languino L.R., Altieri D.C. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. Br. J. Cancer 2011, 104:629-634.
74. Arlander S.J., Eapen A.K., Vroman B.T., McDonald R.J., Toft D.O., Karnitz L.M. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J. Biol. Chem. 2003, 278:52572-52577.
75. Hubbard J., Erlichman C., Toft D.O., Qin R., Stensgard B.A., Felten S., Ten Eyck C., Batzel G., Ivy S.P., Haluska P. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest. New Drugs 2011, 29:473-480.
76. Iyer G., Morris M.J., Rathkopf D., Slovin S.F., Steers M., Larson S.M., Schwartz L.H., Curley T., DeLaCruz A., Ye Q., Heller G., Egorin M.J., Ivy S.P., Rosen N., Scher H.I., Solit D.B. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother. Pharmacol. 2012, 69:1089-1097.
77. Riely G.J., Stoller R., Egorin M., Solit D., Dunbar J., Savage A., Walker J., Grayzel D., Ross R., Weiss G.J. A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel. ASCO Meet. Abstr. 2009, 27:3547.
78. Kauh J.S., Harvey R.D., Owonikoko T.K., El-Rayes B.F., Shin D.M., Murali S., Lewis C.M., Karol M.D., Teofilovici F., Du Y., Fu H., Khuri F.R., Ramalingam S.S. A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies. ASCO Meet. Abstr. 2012, 30:3094.
79. Camphausen K., Tofilon P.J. Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin. Cancer Res. 2007, 13:4326-4330.
80. Bull E.E., Dote H., Brady K.J., Burgan W.E., Carter D.J., Cerra M.A., Oswald K.A., Hollingshead M.G., Camphausen K., Tofilon P.J. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin. Cancer Res. 2004, 10:8077-8084.
81. Enmon R., Yang W.H., Ballangrud A.M., Solit D.B., Heller G., Rosen N., Scher H.I., Sgouros G. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res. 2003, 63:8393-8399.
82. Ochel H.J., Gademann G. In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation. Anticancer Res. 2006, 26:2085-2091.
83. Yu R., Mandlekar S., Ruben S., Ni J., Kong A.N. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res. 2000, 60:2384-2389.
84. Ma Y., Lakshmikanthan V., Lewis R.W., Kumar M.V. Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol. Cancer Ther. 2006, 5:170-178.
85. Georget V., Terouanne B., Nicolas J.C., Sultan C. Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 2002, 41:11824-11831.
86. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., Wongvipat J., Smith-Jones P.M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C.D., Higano C.S., Beer T.M., Hung D.T., Scher H.I., Jung M.E., Sawyers C.L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
87. Zou J., Guo Y., Guettouche T., Smith D.F., Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998, 94:471-480.
88. Zaarur N., Gabai V.L., Porco J.A., Calderwood S., Sherman M.Y. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res. 2006, 66:1783-1791.
89. Dakappagari N., Neely L., Tangri S., Lundgren K., Hipolito L., Estrellado A., Burrows F., Zhang H. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 2010, 15:31-38.
90. Kummar S., Gutierrez M.E., Gardner E.R., Chen X., Figg W.D., Zajac-Kaye M., Chen M., Steinberg S.M., Muir C.A., Yancey M.A., Horneffer Y.R., Juwara L., Melillo G., Ivy S.P., Merino M., Neckers L., Steeg P.S., Conley B.A., Giaccone G., Doroshow J.H., Murgo A.J. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur. J. Cancer 2010, 46:340-347.
91. Ramanathan R.K., Egorin M.J., Erlichman C., Remick S.C., Ramalingam S.S., Naret C., Holleran J.L., TenEyck C.J., Ivy S.P., Belani C.P. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J. Clin. Oncol. 2010, 28:1520-1526.
92. Bagatell R., Paine-Murrieta G.D., Taylor C.W., Pulcini E.J., Akinaga S., Benjamin I.J., Whitesell L. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin. Cancer Res. 2000, 6:3312-3318.
93. Guo F., Rocha K., Bali P., Pranpat M., Fiskus W., Boyapalle S., Kumaraswamy S., Balasis M., Greedy B., Armitage E.S., Lawrence N., Bhalla K. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 2005, 65:10536-10544.
94. McCollum A.K., Teneyck C.J., Sauer B.M., Toft D.O., Erlichman C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res. 2006, 66:10967-10975.
95. Powers M.V., Clarke P.A., Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008, 14:250-262.
96. Lamoureux F., Thomas C., Yin M.J., Kuruma H., Beraldi E., Fazli L., Zoubeidi A., Gleave M.E. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res. 2011, 71:5838-5849.
97. Jhaveri K.L., Iyengar N.M., Corben A., Patil S., Akram M., Towers R., Sakr R., Hudis C., King T.A., Rosen N., Chandarlapaty S., Modi S. Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i). ASCO Meet. Abstr. 2012, 30:10618.
98. Modi S., Stopeck A., Linden H., Solit D., Chandarlapaty S., Rosen N., D'Andrea G., Dickler M., Moynahan M.E., Sugarman S., Ma W., Patil S., Norton L., Hannah A.L., Hudis C. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 2011, 17:5132-5139.
99. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Janne P.A., Lilenbaum R., Gray J.E., Iafrate A.J., Katayama R., Hafeez N., Sweeney J., Walker J.R., Fritz C., Ross R.W., Grayzel D., Engelman J.A., Borger D.R., Paez G., Natale R. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:4953-4960.
100. Wong K., Koczywas M., Goldman J.W., Paschold E.H., Horn L., Lufkin J.M., Blackman R.K., Teofilovici F., Shapiro G., Socinski M.A. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Meet. Abstr. 2011, 29:7500.